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Abstract: Reactive oxygen species (ROS) are important secondary metabolites that play major roles
in signaling pathways, with their levels often used as analytical tools to investigate various cellular
scenarios. They potentially damage genetic material and facilitate tumorigenesis by inhibiting
certain tumor suppressors. In diabetic conditions, substantial levels of ROS stimulate oxidative
stress through specialized precursors and enzymatic activity, while minimum levels are required
for proper wound healing. Photobiomodulation (PBM) uses light to stimulate cellular mechanisms
and facilitate the removal of oxidative stress. Photodynamic therapy (PDT) generates ROS to induce
selective tumor destruction. The regulatory roles of PBM via crosstalk between ROS and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-кB) are substantial for the appropriate
management of various conditions.
Keywords: photobiomodulation; reactive oxygen species (ROS); nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-кB); cancer; diabetes; wound healing
1. Introduction
Reactive oxygen species (ROS) are formed by the fractional reduction of molecular oxygen
and include, but are not limited to, superoxide anions, hydrogen peroxide, and hydroxyl
radicals, all obtained from sequential oxidation–reduction processes involving nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, lipoxygenases, or cyclooxygenases [1]. Unusually high
levels of ROS can allegedly be used for cancer diagnoses, varying according to tumor type, and are potent
signaling molecules in cancer, leading to nuclear damage, genetic instability, and tumorigenesis [2–4].
However, at non-cytotoxic levels, ROS act as secondary messengers with signaling roles in many
physiological systems to activate programmed cell death, gene expression, and other cell signaling
cascades [5]. Increased ROS production was observed in diabetes and diabetic complications,
leading to oxidative stress. As a result, a series of cell death mechanisms were observed within the cell,
finally leading to tissue and organ damage. Elevated levels of blood glucose appear to be the prime
source of free radicals, unbalancing the pool of antioxidants and ROS. Therefore, the down-regulation
of ROS production and targeting factors resulting in their increased generation may have a significant
role in controlling diabetic complications [6,7].
ROS plays a pivotal role in the initial stages of wound healing by killing invading bacteria and
other microorganisms. However, under chronic conditions, increased production of free radicals was
observed, thereby inhibiting the proliferation and migration of key cell types and leading to delayed
wound healing [8,9]. The regulation of certain redox transcription factors is dependent on the level of
ROS. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-кB) was the first discovered
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redox-regulated transcription factor. NF-кB is a protein complex with multiple functions in immune,
inflammation, cell growth, and survival responses. ROS are able to both activate and suppress NF-кB
signaling pathways [10,11]. Photobiomodulation (PBM) is a modern therapeutic approach which
results in beneficial outcomes and the modulation of various signaling pathways in the presence of
light at a specific wavelength. Photodynamic therapy (PDT) uses a specific wavelength light to activate
the photosensitizer to induce cell death in conjunction with molecular oxygen.
Even though PBM is well-known for its cell-stimulating properties both in vitro and in vivo,
clinical studies have been very mixed, and some contradicted non-clinical studies [12–15]; as a result,
some clinicians consider PBM a very controversial therapy [16–18]. It is important to realize that the
underlying cellular mechanisms of PBM are not fully understood [19,20]. Additionally, PBM treatment
parameters vary, such as the wavelength, fluence, power density, pulse structure, and irradiation time.
These are factors that preclude efficient clinical transition of PBM [21–24]. However, some studies
reported the role of cytochrome c oxidase as an important chromophore in the cellular response to
PBM [25]. A similar problem exists with PDT, in that it is not clinically accepted by many clinicians.
Although photodynamic therapy (PDT) has a long history, there is a minimal amount of proven clinical
research, making it difficult for it to be recognized as a first-line treatment approach in modern medicine.
This review focuses on the effect of ROS on NF-кB activity, how ROS are affected by PBM/PDT, and its
role in diabetes, wound healing, and cancer, respectively.
2. Sources and Stimuli of ROS
ROS are oxygen intermediates with unpaired electrons; both superoxide and hydroxyl radicals
are highly unstable oxygen radicals [26]. Experimentally, hydrogen peroxide is a simple peroxide
radical involved in various signaling functions and is frequently used as a source of all oxygen-related
free radicals [27]. Elevated levels of hydrogen peroxide effectively oxidize cysteine residues (Cys-SH)
to cysteine sulfenic acid (Cys-SOH) or cysteine disulphide (Cys-S-S-Cys) in various proteins, such as
kinases, phosphatases, and transcription factors. A well-established mechanism by which ROS regulate
cellular functions is through the redox balance of cysteine residues [28].
Mitochondria and NADPH promote endogenous ROS formation in cancer and reports have shown
crosstalk between these two producers [29]. The mitochondrial oxidative generation of adenosine
triphosphate (ATP) is a major source of free radicals. During the Krebs’s cycle, unpaired electrons are
transferred to the electron transport chain (ETC), resulting in the production of superoxide anions [30].
About ten mitochondrial sites generate numerous superoxide anions through different mechanisms [31].
The reactions of the five complexes of the ETC (complex I to V) are involved in the production of
ATP and free radicals as byproducts. The radicals produced from complexes I and III have various
cellular signaling roles [32]. Both superoxide anions and hydrogen peroxides are constantly produced
by complex III, with 80% released into the intermembrane space and the rest into the mitochondrial
matrix. These ROS intermediate radicals are necessary for cell differentiation, proliferation, survival,
and adaptive immunity responses [33]. In complex IV and during oxidative phosphorylation reactions,
the movement of electrons results in the reduction of oxygen to water. Almost all of the generated
superoxide anions are effectively quenched by manganese superoxide dismutase (MnSOD) to form
hydrogen peroxide, which serves as an important precursor for other free radicals and acts as a
secondary messenger with the ability to diffuse across the mitochondrial membrane, mediated by a
specialized protein from the aquaporin family [33,34]. Other than the positive functions, mitochondrial
ROS also have some deleterious ones, including the formation and progression of various cancer types
like chronic lymphocytic leukemia, acute myelogenous leukemia, and breast cancer [35]. Figure 1
depicts the generation of free radicals and their fate in the ETC. Free radicals formed by the ETC are
immediately removed and converted to water by a series of enzymatic reactions.
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Figure 1. Free radical generation. Free radicals formed by the electron transport chain are immediately
removed and converted to water through a series of enzymatic reactions. ETC: electron transport
chain; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase; GR: glutathione
reductase; PRX: peroxiredoxins; GSH: glutathione; GSSG: glutathione disulfide; Trx: thioredoxin; O2•−:
superoxide; NO•: nitric oxide; ONOO−: peroxynitrite; H2O2−: hydrogen peroxide.
2.1. Oxidative Stress and Cancer
Oxidative damage is linked to all phases of cancer, during which ROS act throughout its
progression. Radicals generated in the mitochondria damage genetic material and produce mutations
that initiate tumor progression due to the imbalance between ROS generation and antioxidant defence
mechanisms [36]. Redox homeostasis is important to sustain normal and survival functions. Increased
aerobic glycolysis and high levels of free radicals in cancer cells are linked to modifications in cell
signaling pathways, which can be counteracted by antioxidant defence mechanisms [37]. ROS facilitate
carcinogenesis by reversibly inhibiting certain tumor suppressors, such as phosphatase and tensin
homolog (PTEN) and protein tyrosine phosphatases (PTPs), which enhance antioxidant expression
and thus decrease ROS levels. However, high levels of ROS are beneficial during the developmental
stages of tumors, promoting cancer vulnerability and death [38].
2.2. Oxidative Stress and Diabetes
Glucose metabolism is the mechanism behind the generation of oxidative stress. In a transition
metal-dependent reaction, the enediol form of glucose is oxidized to enediol anion radicals,
then converted to more reactive superoxide anions and ketoaldehydes. Through a dismutation
reaction, superoxide anions are converted into hydrogen peroxides, which are precursors of highly
reactive hydroxyl radicals. Under diabetic conditions, if these hydrogen peroxides are not degraded
by glutathione peroxidase (GPx) or catalase (CAT), then the production of reactive hydroxyl radicals
occurs in the presence of transition metals [39]. Superoxide radical formation during hyperglycaemia
may also promote additional ROS formation through the oxidation of low-density lipoproteins [40].
Amadori products and advanced glycation end-products (AGEs) are emerging as major precursors
of free radicals in diabetes. AGEs may fluoresce, produce ROS, and bind to specific cell surface
receptors [41]. These generated AGEs bind to their receptors via the receptor for AGEs (RAGE) and
deactivate enzymes, followed by the discharge of free radicals [42]. These enzymatic alterations may
also quench and inhibit the anti-proliferative effect of nitric oxide (NO), which acts as a vital vasodilator
in diabetic patients [43]. Altogether, the increased free radical production stimulates intracellular
oxidative stress by AGEs, which upregulate NF-кB-controlled target genes [44]. In endothelial cells,
ROS stimulates the hexosamine pathway and induces vascular complications in patients with high
blood glucose levels [45]. The overexpression of the enzyme xanthine oxidase may contribute to the
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pathological condition, leading to type 2 diabetes. One of the mechanisms underlying this is the ability
of xanthine oxidase to produce free radicals and oxidative stress [46].
2.3. Oxidative Stress and Wound Healing
The main processes involved in regulated wound healing are migration, adhesion, proliferation,
neovascularization, remodeling, and apoptosis. Imbalance between antioxidants and free radicals with
elevated ROS formation is often observed, followed by the induction of apoptosis. In chronic wounds,
elevated free radicals coupled with reduced antioxidants results in the stimulation of pro-apoptotic
transcription factors, caspase-3, and oxidative stress, leading to cell death and further delays in the
healing process. The development of chronic impaired wound healing involves certain cell signaling
reactions [47]. Fibroblast/keratinocyte cells with mutated mitochondrial DNA result in increased ROS
generation, which affects nuclear transcriptional events by stimulating various signal transduction
pathways and inducing cell cycle arrest, death, and oxidative stress processes [48,49]. In fibroblasts,
mitochondria-generated ROS damages mitochondrial DNA and induces a persistent oxidative stress
condition. Keratinocyte differentiation depends on the ETC for the accumulation of superoxide
anions [50]. In contrast, in normal wound healing, minimal ROS levels mediate intracellular signaling
for cell proliferation and collagen deposition. Low ROS levels and high antioxidant levels are essential
for normal tissue repair [51].
2.4. Influence of Light on Oxidative Stress
Under two different conditions, light is used to either attenuate oxidative stress (as in the case
of PBM) or generate excessive amounts of ROS (as in the case of PDT). PBM involves the use of
non-ionizing radiation or light specifically in the visible and near-infrared regions of the electromagnetic
spectrum for therapeutic applications and stimulation of various cellular mechanisms. When there is
an imbalance between antioxidants and free radicals, PBM facilitates the displacement of free radicals
and the reduction of the oxidative stress load on the organism [52]. The successful action of PBM
depends on the activation of cytochrome c oxidase, which catalyzes the reduction of oxygen to water
by increasing the mitochondrial membrane potential (MMP), ATP, cyclic adenosine monophosphate
(cAMP), and NO [53,54]. NO is an essential signaling agent for the activation of certain cellular
pathways. PBM increases the generation of NO by upregulating cytochrome c levels and/or by cleaving
the metal complexes in cytochrome c [55]. The basic concepts and principles behind PBM are clearly
described in the literature. It is understood that PBM acts on impaired or dysfunctional tissue through
light and leads to mitochondria-mediated cellular processes, thereby inciting various mechanisms that
result in a wide range of therapeutic functions [56]. Some studies proposed that light at wavelengths
between 400 and 500 nm may generate free radicals through photosensitization, while ROS production
by mitochondria was directly evident at longer wavelengths. PBM activates several transcription
factors in the cytosol such as NF-kB, which trigger the transcription of genes and protect cells from
oxidative stress [57].
PDT is a minimally invasive treatment that is becoming commonly accepted as a potential
therapeutic option for localized cancers [58]. PDT depends on the successful accumulation of
photosensitizers (PSs) in tumor cells to initiate the process of irradiation of targeted areas for activation
of the PSs (Figure 2) [59,60]. The wavelength of light should match the absorption properties of
the PSs for effective ROS generation, either through direct electron abstraction (type I) or transfer
from a substrate to oxygen in a highly reactive state (type II), killing targeted tumors and leaving the
neighboring healthy cells unaffected [61]. Due to light inaccessibility to all areas of the body, PDT was
previously limited to superficial conditions, leaving deeper diseased organs less affected. Due to
the advancement in science and the medical use of fiber optics, PDT now has the potential to treat
both superficial lesions and deeper-seated tumors, which were previously inaccessible. The recent
development of wireless photonic and contracted implantable devices for light delivery into deep
regions, such as the brain and liver, rendered PDT treatment even more effective [62].
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Figure 2. During photodynamic therapy (PDT), generated reactive oxygen species (ROS) kill the
targeted tumor cells. PDT depends on the successful accumulation of photosensitizers (PSs) in tumor
cells to initiate the process of irradiation of targeted areas for activation of the PSs. When irradiated with
light of a specific wavelength, a photochemical reaction leads to the production of ROS in the presence
of oxygen. When the PS absorbs the photon energy it is excited and jumps from the ground state to
the excited singlet state and the energy is emitted back as fluorescence or heat via internal conversion.
Should intersystem-crossing occur, the PS is converted to an excited triplet state, which can transfer
electrons with cellular biomolecules, ultimately leading to the generation of ROS in a Type I reaction.
Alternatively, the excited triplet state PS transfers its electrons to ground triplet state molecular oxygen
(3O2), leading to the generation of an excited singlet oxygen (1O2) in a Type II reaction.
2.5. Effect of Light on NF-кB Activation and ROS Regulation.
Activation of NF-кB depends on various parameters, like the cell compartment and dimer
confinement. Cytoplasmic NF-кB dimers are maintained in a stationary and inactive state through their
association with IкB (inhibitor of κB) proteins. When unconfined, NF-кB dimers translocate to nuclear
regions and bind to targeted DNA sequences, promoting gene expression [63]. Other determinant factors
include the synthesis of IкB proteins, activities of IKK (IκB kinase) complexes, and displacement of
NF-кB family members, both transcriptional co-activators and DNA [64]. The N-terminal Rel homology
domain (RHD) has affinities to кB sites and characterizes members of the NF-кB family, consisting of
RelB, RelA/p65, c-Rel, p50 (NF-кB1), and p52 (NF-кB2) in mammals [65]. The binding affinities of
their кB sites are of critical merit to exert positive and negative effects on transcription processes,
dimerization formation, and maintenance [60]. Only p65, RelB, and c-Rel mediate transcription through
their C-terminal transactivation domains (TADs). Though they have no TADs, through interactions
with non-Rel proteins with transactivation ability and hetero-dimerization with TAD-containing
NF-кB subunits, NF-кB1 and NF-кB2 upregulate transcription on the one hand and downregulate
transcription on the other hand via competitive inhibition with TAD-containing dimers [66].
Activation of NF-κB can be observed by direct and indirect glutathionylation of NF-κB and I-κB,
respectively. The p50 of cysteine-62 is sensitive to oxidation, which inhibits the translocation of NF-κB
into the nucleus and prevents DNA binding [67]. However, as S-glutathionylation events occur, p50 is
selectively reduced and DNA binding is restored [68,69]. ROS modification and glutathionylation
of IκBα at cysteine 189 prevents phosphorylation events and degradation, thereby leading to NF-кB
activation and targeted gene transcription (Figure 3) [70]. The IкB-mediated regulation characterizes
the NF-кB pathway and IкB proteins (IкBα, IкBβ, IкBε, IкBz, B-cell lymphoma 3 (BCL-3), and IкBns),
together with the precursor proteins NF-кB1 and NF-кB2, are well defined by the presence of
multiple ankyrin repeat domains. NF-кB activation, via phosphorylation of IкBs on conserved
serine residues, facilitates recognition by bTrCP proteins and K48-linked polyubiquitination by the
Skp1–Culin–Roc1/Rbx1/Hrt-1–F-box family of E3 ligases acting alongside the E2 enzyme UbcH5 in a
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precise manner [63]. The NF-кB signaling pathways are classified into canonical and non-canonical
routes. The canonical route is a classical representation of the generalized regulation of the NF-кB
pathway. Upon ligand recognition, cytokine receptors, such as the antigen receptors, interleukin
(IL)-1 receptor (IL-1R), tumor necrosis factor receptor (TNFR), and pattern recognition receptors
(PRRs), stimulate and activate signaling cascades that culminate in the activation of IKKβ (IKK2). IкB
proteins are phosphorylated by activated IKKβ, which exists in a complex with the closely related
kinase IKKα (IKK1) and NF-кB essential modulator (NEMO, IKKγ). Many membrane-bound ligands,
such as TNFR, TLR, and IL-1R, are involved in activation of the NF-кB pathway and act as upstream
regulators. When activated, the IKK complex becomes the principal upstream part of all NF-кB
pathways, thereby regulating the transcription of proinflammatory genes [71].
Figure 3. Mechanism of photobiomodulation (PBM). When low-powered light (LILI) enters the cell,
it is immediately absorbed by cytochrome c oxidase, which is present in mitochondria. This results in
an increased respiratory chain reaction and the overall redox reaction is altered. The increase in reactive
oxygen species (ROS) stimulates the oxidation of cysteine molecules. The glutathionylation of IkB and
S-glutathionylation of p50 activates NF-kB and transcription of specific genes. This further stimulates
the activation of the IkB kinase complex, leading to phosphorylation, ubiquitination, and degradation of
IkB proteins. Released NF-kB dimers then translocate into the nucleus, bind to specific DNA sequences,
and promote the transcription of target genes such as interleukin (IL)-2, IL-6, IL-8, inducible nitric
oxide synthase (iNOS), COX-2, and matrix metallopeptidases (MMP)-9.
The archetypical IкBα protein promptly degrades during the canonical activation route, causing
the release of multiple NF-кB dimers. IкBα principally targets the p65:p50 heterodimer to form a
IкBα: p65:p50 complex, which has translocating capabilities and masks the p65 nuclear localization
signal. DNA binding is prevented by the IкBa nuclear export signal, which results in steady-state
cytoplasmic localization of NF-кB dimers [72]. The degradation of IкBα leads to localization of NF-кB
in the nucleus and removal of IkB from the NF-кB complex. Then, NF-кB dimers bind to specific
DNA кB sites in the promoters and enhancers of target genes, leading to the formation of homodimers
and heterodimers, and heterotypic interactions with other transcription factors, finally leading to
regulation of transcriptional activity via post-translational modifications of targeted NF-кB subunits [66].
The termination of transcription depends on the synthesis of typical IкB proteins and the elimination
of active NF-кB dimers from DNA. The difference between canonical and non-canonical routes
remains whether they are NEMO-dependent or NEMO-independent. The non-canonical pathway
is NEMO-independent and is determined by IKKα activation to induce the NF-kB/RelB activation
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complex, thereby leading to the generation of a p52/RelB complex and phosphorylation of p100
(Figure 4). IKKα proteins can activate the canonical route and expand to the non-canonical route
through the induction of p100 expression [73].
Figure 4. Activation of NF-кB by the canonical and/or the noncanonical pathway. The canonical NF-
кB-activating pathway depends on the phosphorylation of IкB-kinase (IKK) β. The phosphorylation
and ubiquitination of IкBα translocate NF-кB into the nucleus. where it helps in the transcription of
target genes. Many membrane-bound ligands involved in activating the NF-кB pathway act as effective
upstream regulators and the IKK complex is the common upstream component of all NF-кB pathways.
In contrast, the non-canonical pathway is NF-kB essential modulator (NEMO)-independent and depends
on IKKα activation to induce the NF-kB/RelB activation complex, leading to the phosphorylation of
p100 and the generation of p52/RelB complexes.
2.6. Reciprocal Influence of ROS and NF-кB Activation
Hydrogen peroxide inhibits IKK activation by directly affecting IKKβ through its cysteine
inhibitory ability in catalytic domains of tyrosine phosphatases. The interactions of ROS with cysteine
residues are essential in order to affect the NF-кB pathways [74,75]. They facilitate the phosphorylation
of serine residues in the activation loops of IKK in cells [75], and IKK triggers the ubiquitination
and degradation of IkBα, which is usually phosphorylated on serine 32 and 36 [76]. The kinase
upstream of IKK or mitogen-activated protein kinase 1 (MEKK1) is inactive when glutathionylated at
C1238. ROS also target IKK and affect the NF-кB pathway, S-glutathionylation and IKKB functions via
phosphorylation and degradation of IкBα on tyrosine residues and activation of the NF-кB pathway,
as this may inhibit IкBα phosphorylation. They have the potential to influence the ubiquitination
and degradation of IkB and activate NF-кB by inactivating Ubcl2 [77]. In the non-canonical route,
NF-кB-inducing kinases (NIK), i.e., the upstream kinases, are activated by ROS through inhibition of
phosphatase and oxidation of cysteine residues [78].
Moreover, ROS appear as vital bridging factors that mediate the crosstalk between JNK and NF-кB
signaling pathways and interconnect ROS-mediated NF-кB and cell death, with the ability to inhibit
JNK activation [79]. Furthermore, NF-кB downregulates JNK activation by suppressing TNFα-induced
ROS accumulation. Due to their exerted oxidative stress, ROS directly participate in upregulation or
downregulation of NF-кB through their interactions with cytoplasmic components. ROS are noxious
at certain cellular levels and their inhibition results in the blockage of TNFα-induced programmed cell
death facilitated by the NF-кB signaling pathway [80]. However, nuclear ROS might solely lead to a
reduction of the binding ability of NF-кB to DNA [81]. The respective ROS accumulation and resulting
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oxidative stress generated in a specific subcellular localization becomes significant, as oxidative damage
could be avoided and cell survival could be maintained [82]. Cell survival is the most probable outcome
of the increased expression of NF-кB target genes, and only in a few exceptional cases does a cell death
response prevail. Therefore, it is expected that, on one hand, ROS would modulate NF-кB responses,
and on the other hand, NF-кB target genes would promote survival by ROS attenuation [83].
2.7. NF-кB in Cancer Progression
NF-кB is involved in various stages of oncogenesis and controls the expression of certain
tumor-related genes. During initiation in pre-malignant cells, stimulated NF-кB promotes the expression
of cytokines and chemokines, leading to the recruitment and activation of immune cells, which produce
more chemokines and growth factors [71]. They act on both malignant and inflammatory cells in an
autocrine or paracrine way, creating a complex inflammatory and pro-tumorigenic microenvironment.
NF-кB mediated inflammation contributes to nuclear damage, oncogenic mutation, and tumor
initiation and progression in pre-malignant cells [84]. Epidemiological studies revealed that over
20% of all cancer types are associated with chronic inflammation, which triggers carcinogenic events,
leading to the malignant transformation of normal cells [85]. Abnormal NF-кB activity may promote
the induction of tumors and apoptosis-resistant genes; this is one of the mechanisms by which
resistance to radiotherapy and chemotherapy is acquired. Through cytidine deaminase enzymatic
activity, activation-induced cytidine deaminases (AID) cause genetic alterations in DNA sequences,
and their intrinsic mutagenic-enzyme forms can be induced in response to infectious agents and
pro-inflammatory cytokines that facilitate NF-кB activation in epithelial cells [86]. While the major
role of NF-кB in the regulation of AID expression is evident, NF-кB-mediated AID expression is
accomplished via inflammatory mechanisms for the malignant transformation of epithelial cells during
carcinogenesis. In normal cells, NF-кB is transiently activated, while in cancer cells, it exhibits sustained
activation [87].
NF-кB is involved in tumorigenesis by upregulating the anti-apoptotic pathway and tumor
cell survival. The canonical pathway of NF-кB is known to activate the transcription of a group of
anti-apoptotic proteins, which is further subdivided into two categories, namely, inhibitors of apoptotic
proteins and the Bcl-2 family members [88]. In addition to transcription, inhibition of NF-кB activity
promotes JNK activity and apoptosis, suggesting that NF-кB inhibits apoptosis via inhibition of JNK
activity [89]. Pro-survival functions of NF-кB are related to the expression of phosphoinositide 3-kinase
(PI3K/Akt cascade), one of the key elements in promoting cell proliferation and growth [90] (Figure 5).
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Figure 5. NF-κB activation in the progression of cancer by regulating genes involved in tumor cell
proliferation, cell growth, survival, angiogenesis, tumor promotion, and metastasis. BCL2: B-cell
lymphoma protein 2; BCL-XL, also known as BCL2-like 1; BFL1, also known as BCL2A1; CDK2:
cyclin-dependent kinase 2; COX2: cyclooxygenase 2; CXCL: chemokine (C-X-C motif) ligand; DR: death
receptor; ELAM1: endothelial adhesion molecule 1; FLIP, also known as CASP8; GADD45beta: growth
arrest and DNA-damage-inducible protein beta; HIF1alpha: hypoxia-inducible factor 1 alpha; ICAM1:
intracellular adhesion molecule 1; IEX-1L: radiation-inducible immediate early gene (also known as
IER3); IL: interleukin; iNOS: inducible nitric oxide synthase; KAL1: Kallmann syndrome 1 sequence;
MCP1: monocyte chemoattractant protein 1 (also known as CCL2); MIP2: macrophage inflammatory
protein 2; MMP: matrix metalloproteinase; MnSOD: manganese superoxide dismutase (also known as
SOD2); TNF: tumor necrosis factor; TRAF: TNF receptor-associated factor; uPA: urokinase plasminogen
activator; VCAM1: vascular cell adhesion molecule 1; VEGF: vascular endothelial growth factor; XIAP:
X-linked inhibitor of apoptosis protein.
2.8. NF-кB in the Pathogenesis of Diabetes
Insulin-dependent (type 1) and insulin-independent (type 2) diabetes are the two major variations
of diabetes seen among humans. In type 1 diabetes, beta pancreatic cells are prone to autoimmune
attack by cytokines, such as interferon and IL-1, and NF-кB is mostly inactive in resting cells. However,
IL-1 can activate the translocation of NF-кB to the nucleus [91]. NF-кB regulates the expression
of cytokine-induced genes, which play very significant roles in pro- or anti-apoptotic cascades
(Figure 6). Cytokine-induced NF-кB activation can be reverted by a non-degradable mutant form
of inhibitory кB (IкB) (S32A, S36A) in recombinant adenovirus (AdIB (SA) 2) in human pancreatic
islet cells or by transfection with a stable inhibitor of NF-кB in purified rat cells [92,93]. Moreover,
intravenous administration of a “dummy” NF-кB and mice deficient in NF-кB (p50) showed resistance
to alloxan- and streptozotocin-induced islet cell death [94]. This could be considered a strategy to
protect cytokine-induced in vitro and in vivo apoptosis, whereby inhibition of NF-кB is achieved.
This highlighted the pro-apoptotic effect of NF-кB activation in β-cells of the pancreas. Blocking NF-кB
for a prolonged period displayed impaired development of endocrine cells and expression of important
genes involved in the insulin-secretion pathway [95]. Interestingly, resistance to NF-кB activation
could decrease the time course of the development of diabetes. Hence, it is more important to consider
the mechanisms that regulate NF-кB in cells and genes in diabetic conditions before building up
inhibition strategies.
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Figure 6. Role and activation of NF-кB in diabetes mellitus. NF-кB regulates the expression of
cytokine-induced genes that affect pro- or anti-apoptotic cascades. NF-кB is one of the major causes in
the development of insulin resistance. Tumor necrosis factor (TNF) predominantly induces insulin
resistance by the serine phosphorylation of insulin receptor substrate-1 (IRS1), and NF-кB is a major
cause of insulin resistance.
Type 2 diabetes is mainly characterized by insulin resistance. NF-кB is one of the chief components
in the insulin resistance observed in type 2 diabetes. The anti-inflammatory agent aspirin prevents
the degradation of NF-кB inhibitor (IB), whose expression in the liver attenuates the expression of
NF-кB dependent genes, but also reduced the likelihood of type 2 diabetes development. Similarly,
inflammation-induced hyperglycemia can be inhibited using specific inhibitors of interleukin-1
signaling [96]. Hence, it is obvious that the target genes of NF-кB, such as IL-1, TNF, and IL-6, and NF-кB
itself, play vital roles in insulin resistance. NF-кB also antagonizes peroxisome proliferator-activated
receptor (PPAR), which maintains glucose homeostasis in bone marrow-derived mesenchymal cells [97].
TNF predominantly induces insulin resistance by serine phosphorylation of insulin receptor substrate-1,
which is also a potent activator of NF-кB (Figure 6). Evidence suggests that TNF is involved in insulin
resistance in humans and animal adipose tissue and blocks reversion of the diabetic condition by
masking the activity of NF-кB [98]. Hence, NF-кB is one of the major causes in the development of
insulin resistance. Given the role of NF-кB in insulin regulation, it is important to understand its
beneficial effects in insulin sensitivity and GLUT2 monitoring, a protein that controls glucose-stimulated
insulin secretion by cells [95]. In certain cases, inhibition of the transcription factor NF-кB may inflict
deleterious effects on GLUT 2, leading to diabetes progression. Although there are a lot of studies
highlighting the role of NF-кB in type 1 and 2 diabetes, its specific trail in the pathogenesis of diabetes
requires further investigation.
2.9. NF-кB in Wound Healing
NF-кB is essential for inflammatory and phagocytic cell migration as it strictly regulates
genes involved in cell proliferation (granulocyte colony-stimulating factor and macrophage
colony-stimulating factor), transformation, and survival. In wound healing, the classical NF-кB
pathway is activated as an innate immune reaction and, as a result, activation of NF-кB is more
important in the protection of cells from infections or microbes [63]. The effects of NF-кB on cell
survival mainly depends on the type and number of stimulatory molecules [99]. In normal wound
healing responses, NF-кB functions as a positive signaling molecule to enhance the proliferation phase,
Antioxidants 2019, 8, 640 11 of 16
and both increase and regulate the migration of keratinocytes toward re-epithelization sites [100,101].
Under normal physiological conditions, NF-кB protein levels are standard, hence there is no defined
physiological level to clear dead cells and microbes during responses to infections or wounds. Any
defect in NF-кB activation inhibits the innate immune reaction, whereas the elevated production of
NF-кB increases inflammatory cytokine levels and leads to tumor formation [102]. Every wound is
different and requires integrated defence and repair mechanisms. In clinical settings, wound evaluation
cannot solely depend upon Nrf2 and NF-кB but can indicate an inadequate defence against oxidative
stress or innate immune reactions at large in non-healing wounds. For wounds with prolonged
inflammation, compounds that decrease NF-кB levels or activate the Nrf2 pathway can be useful, and
Nrf2 and NF-кB as markers are mainly utilized to assess healing processes. In immunosuppressed
patients, NF-кB induction can help to initiate the correct immune reaction, but the multifaceted
network of active molecules in the whole body can cause a different cell response than that observed
in vivo [103].
3. Conclusions
Unusually high levels of ROS can allegedly be used for cancer diagnosis, varying according
to tumor type, and are potent signaling molecules in cancer scenarios, thereby leading to nuclear
damage, genetic instability, and tumorigenesis. The regulation of redox transcription factors is
dependent on the generation of ROS levels. NF-кB was the first redox-regulated transcription factor
to be discovered. It is a protein complex with multiple functions in immune, inflammation, cell
growth, and survival responses. ROS have NF-кB stimulatory effects in the cytoplasm and inhibitory
effects in the nucleus. Therefore, ROS have the ability to both activate and suppress NF-кB signaling
pathways. PBM promotes photon availability and absorption by chromophores in the catalytic center
of mitochondrial cytochrome c oxidase the and subsequent reduction of molecular oxygen. This
disturbs the mitochondrial membrane potential and changes the fission–fusion homeostasis in the
mitochondrial network, leading to increased levels of intermediates such as ATP, cAMP, and ROS.
PBM-mediated ROS interact with certain family proteins that enclose highly reactive cysteine (Cys)
residues and after the oxidation of Cys residues. The activity of NF-кB is regulated by direct activation
or after disassembling from IkB, an inhibitor, then the released NF-кB translocate to the nucleus and
promotes gene transcription. The regulation of crosstalk between ROS and NF-кB appears to be a
key factor for better management of many conditions. PBM facilitates the reduction of oxidative
stress and activation of mechanisms that upregulate or downregulate NF-кB, which are critical for the
promotion of anti-apoptotic responses and tumor progression, insulin dependence or resistance in
diabetes, cell proliferation and migration in wounded sites, or cell survival by ROS attenuation.
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